NAD+ Side Effects: What to Watch, and When
The effects people describe during a drip track the rate it runs at. The risks that would actually hurt someone sit elsewhere entirely.
NAD+ side effects are usually written up as one list, which hides the thing that decides them. There are at least three different products in circulation under this name, they enter the body by different routes, and their risks have almost nothing in common. Sorting by route first, and by severity second, produces a far more useful page than the alphabetical list of symptoms most sites publish.
Where the order actually gets placed
Ascension Peptides, NAD+
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked August 20, 2026.
Sorting NAD+ side effects by route before sorting them by severity
The three routes are an intravenous infusion given in a clinic, a precursor capsule swallowed at home, and a vial of powder mixed and injected by the buyer. They are not versions of one another.
The infusion is the only one with a distinctive short term experience attached, and it is the one people are usually asking about. The capsule has the best documented profile, because it is the form that has been through interventional trials in humans, but those trials studied nicotinamide riboside and nicotinamide mononucleotide rather than the assembled coenzyme. The home mixed vial has no published profile whatsoever, and it carries a category of risk the other two do not, because nobody has verified what is in it.
Anyone summarising the three together produces a list that is simultaneously alarming about the wrong things and silent about the right ones.
During the drip, where the effects track the rate rather than the quantity
The clinics that sell these infusions are consistent about one thing, and it is the most reliably reported detail in the whole subject.
Practitioners and clients describe warmth, flushing, a tight or pressured feeling in the chest, nausea, abdominal cramping and a general urge for the session to be over, and they describe these appearing when the drip runs quickly and easing when it is slowed. That is why an appointment takes hours rather than minutes. The pace is set by tolerability, not by any published pharmacokinetic reasoning about what concentration is needed.
Two points follow, and they run in opposite directions. The first is reassuring in a narrow way: an effect that appears with speed and resolves when the speed drops is behaving like an infusion reaction rather than like organ damage. The second is not reassuring at all: none of this is trial safety data. It is accumulated practitioner impression from a service sold without regulatory oversight, reported by the people selling it. Absence of published problems from an unmonitored setting is not a safety record. It is the absence of a record.
The hours afterwards, and the following days
What is described after a session is thinner and less consistent: tiredness for the rest of the day in some accounts, a headache, occasionally a period of feeling unusually alert. None of it has been measured against a comparison group, and all of it is exactly what an expensive, long, physically eventful afternoon produces on its own.
The infusion site is worth more attention than the systemic story, because it is concrete. A cannula that has been in place for hours can leave bruising, local tenderness or inflammation of the vein, and fluid can leak into the surrounding tissue if the line moves. These are ordinary intravenous risks, they are not specific to this molecule, and they are the complications a clinic should be equipped to recognise.
The risks that belong to the vial and the room, not to the molecule
This is the part that gets left out, and it is where the serious harm sits.
There is no marketing authorisation for the injected form as a treatment. That has a practical consequence rather than a merely bureaucratic one: nothing in the supply chain is subject to the checks that apply to a licensed injectable. Identity, purity, endotoxin content and sterility are assurances the buyer is being asked to take on trust.
For an infusion, the sterility question is the one that matters. Anything going into a vein bypasses every barrier the body has, and a contaminated preparation produces a bloodstream infection, which is a medical emergency and not a side effect in the ordinary sense. For a home mixed vial the same risk applies with fewer people watching, plus the risks of a buyer reconstituting a powder without training, and plus the possibility that the contents are not what the label says at all.
Ranked honestly, an unverified product injected outside clinical supervision is the largest hazard in this entire subject, and it has nothing to do with the coenzyme's biology.
Oral precursors, which have the better documented profile
The capsules are the one place where a real tolerability record exists.
In human trials of nicotinamide riboside and nicotinamide mononucleotide, the reported adverse events have generally been mild and often gastrointestinal: nausea, loose stools, stomach discomfort. Those trials were short and were not designed to detect uncommon events, so the correct summary is that no frequent serious problem appeared over the periods studied, which is a narrower statement than safe.
Two related compounds deserve separate mention because they are often shelved together. Nicotinic acid, the other vitamin B3 form, produces the well known flushing reaction, and high doses of it have long been associated with liver effects in people. Nicotinamide does not flush. Neither observation transfers automatically to the precursors or to an infusion, but a buyer reading a B3 aisle should know that the forms behave differently.
What cannot be ruled out from a page like this one
Two categories stay open and no honest article can close them.
The first is interaction. Anyone on prescribed medication, particularly anything affecting the liver, blood pressure or blood glucose, is asking a question that requires their own prescriber and their own list. A general page cannot answer it, and clinic intake forms are not a substitute for that conversation.
The second is the long term. For the injected form, nobody has followed anyone for years under measurement. The mechanism being marketed involves enzymes that regulate cell growth and DNA repair, which is a reason to want long term data rather than a reason to assume harm, and the point is simply that the data does not exist. A compound whose entire selling proposition is a change over decades has been studied over an afternoon.
| Effect or risk | Which intervention | When it would show | How well documented |
|---|---|---|---|
| Flushing, chest tightness, nausea, cramping | Intravenous infusion | Minutes into the drip, eases when slowed | Practitioner and client report only |
| Bruising, vein inflammation, fluid leak | Any intravenous line | During or shortly after the session | Standard intravenous risk in humans |
| Bloodstream infection | Non sterile infusion or home injection | Hours to days after | Established risk of any unverified injectable |
| Mild digestive upset | Oral nicotinamide riboside or mononucleotide | Within days, in human trials | Reported in short human trials |
| Flushing and liver effects at high dose | Nicotinic acid, a different B3 form | Immediate for flush, longer for liver | Long established in people |
| Anything appearing after years | Injected coenzyme | Unknown | Nobody has looked |